These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795 [TBL] [Abstract][Full Text] [Related]
49. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487 [TBL] [Abstract][Full Text] [Related]
50. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis. Kawaguchi N; Katsube T; Echols R; Wajima T Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272 [TBL] [Abstract][Full Text] [Related]
51. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms. Domingues S; Lima T; Saavedra MJ; Da Silva GJ Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802 [TBL] [Abstract][Full Text] [Related]
52. Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms. Sajib MI; Monteforte M; Go R Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237839 [TBL] [Abstract][Full Text] [Related]
53. Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F; Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963 [TBL] [Abstract][Full Text] [Related]
54. Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. Kawai A; Shropshire WC; Suzuki M; Borjan J; Aitken SL; Bachman WC; McElheny CL; Bhatti MM; Shields RK; Shelburne SA; Doi Y mBio; 2024 Feb; 15(2):e0287423. PubMed ID: 38179965 [TBL] [Abstract][Full Text] [Related]
55. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M; Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840 [TBL] [Abstract][Full Text] [Related]
56. Imipenem-Relebactam Susceptibility in Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877 [TBL] [Abstract][Full Text] [Related]
57. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria. Yamano Y Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049 [TBL] [Abstract][Full Text] [Related]
58. Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Karakonstantis S; Rousaki M; Kritsotakis EI Antibiotics (Basel); 2022 May; 11(6):. PubMed ID: 35740130 [TBL] [Abstract][Full Text] [Related]
59. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India. Nayak G; Behera B; Mohanty S; Kar P; Jena J Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292 [TBL] [Abstract][Full Text] [Related]